A Phase II, Randomized, 4-Week, Double-Blind, Placebo-Controlled, Multiple-Dose Study, Designed to Determine the Safety, Tolerability, EEG Effects and Preliminary Efficacy of Fixed Oral Doses of 7.5 and 15 MG BID of Evenamide in Patients With Chronic Schizophrenia Who Are Symptomatic on Their Current Second-Generation Antipsychotic Medication
Latest Information Update: 23 Sep 2024
At a glance
- Drugs Evenamide (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Newron Pharmaceuticals
- 19 Sep 2024 According to a Newron Pharmaceuticals media release, company will be presenting the results of study 008A at the upcoming 37th ECNP Congress (September 21-24, 2024) in Milan, Italy.
- 19 Sep 2024 According to a Newron Pharmaceuticals media release, compelling data from additional analyses from this trial presented in May 2024.
- 17 May 2021 Status changed from active, no longer recruiting to completed.